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Abstract 
Background: The ideal protein expression system should provide recombinant proteins in high quality and quantity 
involving low production costs only. However, especially for complex therapeutic proteins like monoclonal antibod‑
ies many challenges remain to meet this goal and up to now production of monoclonal antibodies is very costly and 
delicate. Particularly, emerging disease outbreaks like Ebola virus in Western Africa in 2014–2016 make it necessary to 
reevaluate existing production platforms and develop robust and cheap alternatives that are easy to handle.
Results: In this study, we engineered the microalga Phaeodactylum tricornutum to produce monoclonal IgG antibod‑
ies against the nucleoprotein of Marburg virus, a close relative of Ebola virus causing severe hemorrhagic fever with 
high fatality rates in humans. Sequences for both chains of a mouse IgG antibody were retrieved from a murine hybri‑
doma cell line and implemented in the microalgal system. Fully assembled antibodies were shown to be secreted by 
the alga and antibodies were proven to be functional in western blot, ELISA as well as IFA studies just like the original 
hybridoma produced IgG. Furthermore, synthetic variants with constant regions of a rabbit IgG and human IgG with 
optimized codon usage were produced and characterized.
Conclusions: This study highlights the potential of microalgae as robust and low cost expression platform for mono‑
clonal antibodies secreting IgG antibodies directly into the culture medium. Microalgae possess rapid growth rates, 
need basically only water, air and sunlight for cultivation and are very easy to handle.
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Background
Antibodies are important tools in diagnostics as well 
as in therapy and monoclonal antibodies currently rep-
resent one of the best-selling classes of biologics with 
US sales reaching 20.3 billion dollar in 2011 [1]. At the 
moment monoclonal antibodies are produced mainly in 
mammalian cell lines e.g. Chinese hamster ovary (CHO) 
cells [2, 3]. However, mammalian cell culture is very 
expensive to propagate and always bears the risk that 
cultures get contaminated with human pathogens rep-
resenting serious bottlenecks for large scale production 
[4, 5]. Hence, alternative and safe expression systems for 
recombinant antibodies and lower production costs are 
highly desirable.
Bacteria and yeast are robust high yield expression sys-
tems widely used in biotechnology and currently provide 
a platform for the production of small synthetic antibody 
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variants like single chain antibodies and nanobodies, 
which are interesting for therapeutic applications due 
to improved tissue penetration [6, 7]. The production of 
complex eukaryotic molecules like assembled IgG anti-
bodies, which require a sophisticated folding machinery 
as well as eukaryotic post translational modifications, 
remain more challenging [8, 9]. Only recently though, it 
was shown that high level expression of fully assembled 
IgG antibodies within the cytoplasma of engineered E. 
coli cells is feasible representing a break through for 
low cost production of aglycosylated antibodies [10]. 
In the late 1990s plants came into focus as solar-fueled 
expression systems and the concept of molecular farm-
ing gained interest for production of edible vaccines 
but also for potential low-cost production of antibodies 
[11–14]. Today there are different examples for high level 
transient expression of monoclonal antibodies in glyco-
modified plants [15]. A direct comparison of monoclonal 
antibodies produced in plants and CHO cells revealed 
that plant produced antibodies against Ebola virus can 
be as effective as antibodies from CHO cells in  vitro as 
well as in therapeutic studies with animal models [16, 
17]. Nevertheless, cell culture based approaches (with 
higher plant cells or moss) with the antibody being 
secreted into the culture medium might be transferred 
to industrial scale more easily [18–20]. Much progress on 
plant produced antibodies has also been made in terms 
of glyco-engineering providing strains with humanized 
glycosylation profiles producing antibodies with a very 
homogenous glycopattern that show enhanced ADCC 
(antibody-dependent cell-mediated cytotoxicity) com-
pared to mammalian antibodies [17, 21, 22].
Microalgae are currently in the focus of biotech-
nology due to high lipid content interesting for sus-
tainable biodiesel production [23–26]. Additionally, 
microalgae-based production of recombinant proteins 
is highly interesting because algae are like land plants 
fueled by photosynthesis, the cultivation costs are very 
low and biomass productivity is much higher than for 
plants. Microalgae combine advantages of different 
expression systems as they are like prokaryotic systems 
very easy to handle, possess high growth rates, are very 
robust and easily scalable [27–30]. Furthermore micro-
algae provide eukaryotic modifications like N-glyco-
sylation, which is important for the production of many 
mammalian proteins and might in future be engineered 
towards human specific profiles [31–33]. Many algal 
species are regarded as safe, they are no hosts to known 
human pathogens and have been used as nutrition sup-
plements for many decades making them interesting 
especially for the production of therapeutic proteins [28, 
34]. In 2003, a large single chain antibody was the first 
antibody produced in the plastid of Chlamydomonas 
reinhardtii [35] and 6  years later it was demonstrated 
that also a functional IgG antibody can be produced in 
the plastid of that model alga [36]. However, the produc-
tion level was rather low, antibodies had to be extracted 
from the cells and lacked eukaryotic modifications which 
are not provided in chloroplasts. In the following years 
also synthetic antibodies like single chain immunotox-
ins and variants like camelid antibodies have been pro-
duced in the chloroplast of C. reinhardtii, which might 
provide several advantages over bacterial expression 
[37–39]. In 2011 it was shown in the diatom Phaeodacty-
lum tricornutum that a human IgG antibody against the 
Hepatitis B Virus surface protein can be expressed very 
efficiently from the nuclear genome reaching production 
levels of ~9% of total soluble protein [40]. Further analy-
ses revealed that the human IgG antibody can also be 
secreted into the culture medium [41]. The antibody was 
fully assembled, functional and without further purifica-
tion steps already very pure as the alga seems to secret 
barely other proteins demonstrating the great potential 
of using microalgae as expression system for monoclonal 
IgG antibodies. A biochemical characterization of the P. 
tricornutum produced antibodies demonstrated that the 
immunoglobulins possess homogeneous C-terminal ends 
without proteolysis and carry high mannose-type N-gly-
cans, which might be engineered towards human specific 
glycopatterns in future [33].
In this study, we implemented our previously estab-
lished diatom system for generating monoclonal anti-
bodies against the highly pathogenic Marburg virus 
(MARV). MARV belongs together with Ebola virus to the 
virus family Filoviridae which are the causative agents 
for severe hemorrhagic fevers with high fatality rates 
in humans. Filoviruses are endemic in Africa and their 
potential to threaten private and public health is high, as 
it was seen during the recent outbreak of Ebola virus in 
West-Africa (2014–2016) with more than 28,000 infec-
tions and more than 11,000 fatalities. So far, neither for 
Ebola virus nor for MARV licensed vaccines or treat-
ments for human use are available. MARV particles con-
sist of seven viral proteins. One of the main components 
of the viral transcription and replication complex is the 
nucleoprotein (NP) which encapsidates the viral genomic 
RNA. Although NP is a major target of antibodies in 
the infected mammalian host their function is currently 
enigmatic [42]. In order to implement the diatom system 
for the generation of a MARV-specific monoclonal anti-
body, we used a previously generated mouse monoclonal 
antibody against the MARV NP. We retrieved sequences 
for the light and heavy chain of the murine IgG antibody 
against the NP directly from the respective hybridoma 
cell line, expressed the antibody in the microalga P. tri-
cornutum and compared its functionality directly to the 
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original hybridoma produced antibody. The antibody 
is secreted by the diatom as completely assembled mol-
ecule into the algal culture medium and was character-
ized and tested in different applications such as western 
blot assays, ELISA, as well as immunofluorescence con-
firming the high quality of the algal produced antibody. 
Besides the original IgG antibody two chimeric antibod-
ies with rabbit and human Fc-regions, respectively, were 
generated and expressed in the alga. All variants were 
proven to be functional demonstrating the ease of using 
P. tricornutum as a low-cost expression system for IgG 
antibodies.
Results
Expression and secretion of fully assembled α MARV NP 
antibodies by P. tricornutum
Sequences for antibodies against the Marburg virus 
nucleoprotein (MARV NP) are not known so far. Hence, 
in a first step cDNA sequences encoding the light 
and heavy chain of an α MARV NP IgG antibody were 
retrieved from an existing hybridoma cell line. Nucleo-
tide sequences were amplified via RT-PCR (GenBank: 
KY441466, KY441467) using a set of degenerate primers 
described previously by Wang et al. and Li et al. [43, 44]. 
Besides the full length sequences for the light and heavy 
chain, two aberrant forms were detected for the light 
chain. One sequence corresponded to the non-functional 
form κ-138 which is commonly found in hybridoma cell 
lines generated with SP2/0-Ag14 cells and traces back to 
the fusion partner [45], the second aberrant sequence was 
not reported so far (GenBank: FN422002.1, KY441468). 
Altogether, the full length sequences including the signal 
peptides were amplified and allowed a broad application 
spectrum e.g. the heterologous expression of the com-
plete IgG antibody but also the production of synthetic 
variants like chimeric humanized IgG antibodies inter-
esting for therapeutic applications.
Initially, the sequences for heavy and light chain of the 
murine MARV NP antibody were expressed as eGFP 
fusion constructs in P. tricornutum to check whether 
expression of the antibody chains and their targeting to 
the endoplasmatic reticulum is supported by the heter-
ologous expression system. For both fusion proteins a 
typical ER localization was observed (Fig.  1a). Subse-
quently, both sequences were expressed in one cell line 
without the eGFP fusion part under the control of the 
inducible nitrate reductase promoter of P. tricornutum. 
The antibody was expressed by the alga and secreted into 
the culture medium. For a first check on antibody qual-
ity, proteins of 30 ml medium were separated by SDS gel 
electrophoresis and stained with Coomassie demonstrat-
ing that the secreted antibody is already relatively pure 
(Fig.  1b). In the following, antibody functionality was 
tested in different assays and specificity was compared 
directly to the purified mouse hybridoma antibody.
Algae vs. hybridoma produced antibody
Non-reducing SDS gel electrophoresis and western blot 
analyses demonstrated that the antibodies secreted by 
the alga are assembled in a high molecular weight com-
plex of about 170 kDa corresponding to an IgG molecule 
consisting of two heavy and two light chains (Fig.  1c). 
Additionally, some lower molecular weight signals were 
detected, but no significant difference compared to the 
purified MARV NP antibody produced by the hybridoma 
cell line was observed. In further assays, the specificity 
of the antibody, i.e. its ability to bind to the target anti-
gen, was tested in different in vitro assays. For testing the 
algal produced antibody in western blot analysis, HuH7 
cells were infected with Marburg virus at a MOI of 1 and 
lysed 20  h post infection. Cell lysates were inactivated 
and aliquots were processed by SDS PAGE and west-
ern blotting. The hybridoma and the alga NP-specific 
antibodies were used to detect NP at a concentration of 
500  ng/µl. Both antibodies showed a comparable sensi-
tivity for NP (Fig. 2a). Furthermore, ELISA studies were 
performed to investigate whether the antibody is able 
to bind to native MARV NP, as well. For these studies 
150 ng of recombinant MARV NP were coated to wells 
and antibody binding was tested. The assay demonstrated 
that the antibody secreted by the alga was also fully func-
tional in ELISA (Fig. 2b). However, the binding efficiency 
was slightly lower compared to the purified hybridoma 
antibody. To exclude inhibitory effects of other proteins 
within the medium of the alga and to improve antibody 
quality, the algal produced antibody was purified with 
protein A agarose. Antibody purification had no signifi-
cant effect on binding efficiency in ELISA (Additional 
file  1). However, the Coomassie staining of the purified 
antibody revealed a weak additional signal for a HC vari-
ant with slightly reduced molecular weight (Fig. 1b) (veri-
fied by mass spectrometry), which might be a reason for 
slightly impaired binding compared to the original hybri-
doma produced antibody. Finally, the algal antibody was 
tested in immunofluorescence analysis. Huh7 cells were 
infected with MARV (MOI 1) for 20 h. Cells were fixed, 
inactivated and stained with the algal produced and 
the original hybridoma antibody. Again, both antibod-
ies clearly recognized the typical viral inclusion bodies 
which are formed during viral infection due to NP accu-
mulation [46] (Fig. 2c).
Expression of synthetic antibody variants
On the basis of the cDNA sequences that were obtained 
for the light and heavy chain of the MARV-NP antibody 
and published sequences for other mammalian IgGs, 
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chimeric antibody variants with either rabbit or human 
Fc-regions were generated and expressed in P.  tricor-
nutum (GenBank: KY441469, KY441470, KY441471, 
KY441472). Especially humanized antibodies are of 
course interesting for potential therapeutic applications. 
Sequences for the constant regions of rabbit and human 
IgG were synthesized (by Life Technologies) and fused 
to the variable regions via PCR or via cloning. In case 
of the humanized antibody the codon usage of the com-
plete sequence was adapted to P. tricornutum codon 
(See figure on previous page.) 
Fig. 1 Phaeodactylum tricornutum secretes fully assembled α MARV NP IgG antibodies into the medium. a In vivo localization studies on the 
expression of heavy and light α MARV NP antibody chains in P. tricornutum. Sequences for the light and heavy chain of the murine IgG2a antibody 
against the Marburg virus nucleoprotein were retrieved from a hybridoma cell line and expressed as GFP fusion proteins in the diatom P. tricor-
nutum. Both fusion proteins are expressed in the heterologous system without codon optimization and accumulate within the ER of the cells 
demonstrating that the murine signal peptide is sufficient for ER targeting. Scale bar represents 10 µm. b Purity analysis of secreted α MARV NP 
IgG antibodies. Proteins of 30 ml culture medium were concentrated with centrifugal filter units (cut off of 10 kDa), separated by SDS‑PAGE and 
stained with Coomassie. Besides the antibody heavy and light chain (marked with asterisks) two dominant signals were detected at ~130 kDa 
representing a known phosphatase (Phatr2 ID: 47612, verified by mass spectrometry). After protein A purification no background remained, but 
a weak signal for a HC variant with reduced molecular weight is detected (verified by mass spectrometry). c Biochemical analyses of secreted α 
MARV NP IgG antibodies. 100 ng of purified hybridoma produced antibody and antibody from the algal medium were prepared under reduced and 
non reduced conditions, separated by SDS‑PAGE and analysed in western blot studies using an α mouse secondary antibody for detection. Under 
reduced conditions heavy and light chain of the antibody are clearly separated and appear as distinct signals of 55 and 30 kDa. In case of the algal 
produced antibody the light chain seems to accumulate to slightly higher amounts. Under non reduced conditions disulfide bridges stay intact and 
the assembled antibody consisting of two heavy and two light chains is detected with a size of about 170 kDa. Lower molecular weight signals are 
observed in case of both antibodies with no significant difference. Ab antibody, HC heavy chain, LC light chain, MARV Marburg virus, NP nucleopro‑
tein, PAF plastid autofluorescence
Fig. 2 Comparing functionality of algae and hybridoma produced α MARV NP antibodies in different in vitro assays. a Western blot analyses dem‑
onstrate that algae and hybridoma produced antibodies recognize the MARV NP protein equally good. Cell extract of MARV infected HuH7 cells 
was separated by SDS‑PAGE, followed by western blot analyses using 500 ng/ml antibody for detection. In case of both antibodies the nucleopro‑
tein is detected with a clear and distinct signal at about 120 kDa. b ELISA studies measuring the binding affinity for MARV NP protein reveal that the 
algal produced antibody, which was retrieved directly from the culture medium is able to bind the native protein, but not as good as the hybri‑
doma produced antibody. Medium of wild type cells and samples without NP protein served as negative controls. c Immunofluorescence assays 
with MARV infected HuH7 cells (20 h post infection) show for both antibodies a clear labeling for MARV NP, which accumulates in dot like structures 
(green) around the nucleus (blue DAPI stained). No labeling is observed for mock HuH7 cells. Error bars indicate standard deviation (n = 3)
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usage. Assembly assays demonstrated that the chimeric 
IgG antibodies were correctly folded and secreted as a 
fully assembled complex (Fig. 3a). In case of the human-
ized version, the non-reduced sample showed beside 
the 170  kDa signal a distinct signal of approximately 
130  kDa. This pattern was also observed when using a 
human IgG standard and might represent an interme-
diate complex being the result of fragmentation during 
sample preparation (Fig. 3a). The ability of the chimeric 
antibody variants to bind MARV-NP protein was con-
firmed in western blot assays using secondary antibod-
ies against rabbit and human IgG, respectively (Fig. 3b). 
Quantification assays gave a yield of about 1300  ng/ml 
secreted antibody in case of the humanized version and 
approximately 500 ng/ml in case of the murine antibody.
Discussion
Monoclonal antibodies are important instruments in 
immunotherapy of cancer, autoimmune diseases and 
Alzheimer disease and the production of monoclonal 
antibodies in CHO cells has become a multibillion dol-
lar industry worldwide. However, high production costs 
and potential virus contamination represent critical 
drawbacks and hence alternative production platforms 
are required. Here, we implemented diatoms as a plat-
form for the generation of a mouse monoclonal anti-
body against the highly pathogenic MARV. MARV is 
closely related to Ebola virus (family Filoviridae); both are 
endemic in Africa causing severe hemorrhagic fevers in 
humans and nonhuman primates. To date, there are nei-
ther licensed vaccines nor therapeutics available against 
Marburg or Ebola virus infections in humans. Therefore, 
containment of Marburg or Ebola virus outbreaks is rely-
ing on a rapid response mechanism in order to mitigate 
their consequences. Novel strategies to combat filovirus 
outbreaks include the large scale production and use 
of neutralizing monoclonal antibodies as a therapeutic 
tool. A recent example is a cocktail of monoclonal anti-
bodies (ZMapp) against Ebola virus which was used as 
experimental therapy during the Ebola virus outbreak 
in West-Africa in 2014–2016 [47]. Furthermore, a single 
monoclonal antibody, isolated from a survivor of Ebola, 
was shown to protect nonhuman primates even 5  days 
post infection [48] demonstrating the great potential 
of antibody therapies not only for chronic diseases and 
cancer but also infectious disease. Additionally, single-
domain antibodies were demonstrated as reliable and fast 
diagnostic tools as it has been shown for IgG and llama 
single domain antibodies against MARV NP [49, 50]. In 
this study, we tested our previously described diatom sys-
tem for the rapid generation of a monoclonal mouse anti-
body against the nucleoprotein of Marburg virus.
We retrieved sequences for the heavy and light chain 
of an IgG2a antibody against MARV NP from a murine 
hybridoma cell line, which is to our knowledge the first 
published sequence of a MARV NP antibody. Subse-
quently, both sequences including the murine signal pep-
tides were expressed within the microalga P. tricornutum 
Fig. 3 Production of chimeric α MARV NP IgG antibodies in P. tricornutum. a Chimeric antibody variants with rabbit and human Fc‑regions are like 
the original murine IgG complex secreted by P. tricornutum. The secreted antibodies are assembled as demonstrated by gelelectrophoretic separa‑
tion of reduced and non‑reduced samples followed by western blot assays with α human and α rabbit secondary antibodies respectively (100 ng 
of algal produced antibody were loaded). Beside the ~170 kDa signal of the completely assembled IgG complex a second signal of about 130 kDa 
was detected for the humanized antibody version, however this is also true for a sample of human IgG standard. b Western blot assays using both 
chimeric variants as detection antibody for MARV NP demonstrate that both antibodies are functional and recognize the target antigen. Cell extract 
of MARV infected HuH7 cells was separated by SDS‑PAGE, followed by western blot analyses using 500 ng/ml antibody for detection
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resulting in completely assembled and functional IgG anti-
bodies secreted into the medium. Functionality of the anti-
body was tested in WB and IFA assays demonstrating that 
the quality of the algal produced antibody is comparable 
to the original hybridoma produced antibody. In ELISA 
the algal produced antibody showed in comparison to the 
original hybridoma produced antibody reduced binding 
affinity, which might be due to partially inaccurate sig-
nal peptide cleavage (as it was observed for another IgG 
produced in P. tricornutum [33]). Indeed, the additional 
HC variant detected after protein A purification (Fig. 1b) 
might be a result of partially inaccurate processing of the 
signal peptide, a problem that might be overcome by using 
endogenous targeting signals in future. The expression 
level for this murine antibody was with 500 ng/ml medium 
lower than for the previously in P. tricornutum expressed 
human IgG [41], which reached expression levels of 
2500 ng/ml [41]. However, the murine sequences that were 
retrieved from the hybridoma cell line were expressed 
without codon-optimization, which probably represents 
the main reason for lower expression levels. This was 
confirmed by using a chimeric immunoglobulin with the 
constant part of a human IgG antibody and full codon-
optimization within the variable regions, which showed 
expression levels of about 1300  ng/ml. In this study, no 
further strategies for expression optimization were applied 
but preliminary studies indicate that for example multiple 
integration events of the plasmid can enhance expression 
levels. With regard to cell culture the cell density is cer-
tainly another way to optimize antibody production. In 
the present studies cells were grown in Erlenmeyer flasks 
with optical cell densities of approximately 2 (OD 600nm) 
as a maximum, however large scale cultivation conditions 
e.g. using flat panel reactors with continuous feeding will 
result in much higher cell densities and potentially provide 
much higher antibody concentrations in the medium.
Conclusions
This study highlights the ease and great potential of using 
microalgae as expression system for monoclonal antibod-
ies. It took only a few weeks from sequence retrieval to 
the generation of microalgae secreting the antibody into 
the culture medium and as the antibodies within the salt 
water medium are already relatively pure, downstream 
processing is facilitated remarkably. Microalgae repre-
sent an attractive and robust production platform as they 
are easy to handle, provide rapid growth rates at low cost 
since they need basically only light, air and water. Further-
more, microalgae are no host for human pathogens, mini-
mizing the risk for human pathogenic contaminations—a 
further important safety and cost factor for the produc-
tion of therapeutic proteins. While microalgal antibody 
production can presently not compete with mammalian 
systems in terms of production efficiency, future bioengi-
neering of algae will certainly improve expression levels, 
secretion performance and enable the humanization of 
glycosylation patterns. The dramatic Ebola outbreak in 
West Africa clearly demands robust and fast expression 
systems for therapeutic antibodies that can be handled 
easily and at low cost eventually even on-site, which might 
be feasible with a microalgal system in future.
Methods
Amplification of heavy and light antibody chains 
and plasmid construction
RNA of 0.5  ×  106 cells of hybridoma cell line MARV 
59-9-10-7 (SP2/0-Ag14 + BALB/c), producing an IgG2a 
antibody against MARV NP protein (BioGenes GmbH), 
was isolated with the RNeasy Plus Mini Kit (Quiagen). 
cDNA was generated using 1  µg RNA, (dT)18 oligonu-
cleotides and Superscript II reverse transcriptase accord-
ing to manufacturer’s instructions. Amplification of the 
sequences for the heavy and the light antibody chain was 
performed with Taq polymerase according to [44]. A set 
of degenerate oligonucleotides binding in the 5′-region 
of the signal peptide [43] and oligonucleotides binding 
in the constant region of light and heavy chain [44] was 
tested for initial amplification of the variable region of 
both antibody chains. For final amplifications of the full-
length sequences and the insertion of restriction sites 





expression of the complete antibody both sequences were 
cloned in the plasmid pPha-DUAL-[2 × NR] (Genbank: 
JN180664), which carries two multiple cloning sites both 
being under the control of P. tricornutum nitrate reduc-
tase promoter/terminator. For in vivo localization studies 
the sequences were fused with the sequence of eGFP and 
cloned into the plasmid pPha-NR (Genbank: JN180663). 
Chimeric sequences with rabbit and human Fc-regions 
were generated either by fusion-PCR or by introducing 
the restriction site BglII within the linker region and fus-
ing variable and constant parts by cloning. Templates for 
the constant regions of human and rabbit IgGs were syn-
thesized by Life Technologies.
Antibody expression, harvesting and quantification
Phaeodactylum tricornutum (Bohlin, University of Texas 
Culture Collection, strain 646) was stably transfected 
by biolistic transfection as described previously [51] 
using M10 tungsten particles and 1350 psi rupture discs 
together with the particle delivery system Bio-Rad Biolis-
tic PDS-1000/He. Cells were cultivated in f/2 medium 
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under constant illumination (80  μmol photons/m2  s1) 
at 22  °C. In contrast to standard f/2 medium (based on 
the f medium of Guillard and Ryther 1962 with all sup-
plements reduced by half ) cells were grown with 1.6% 
tropic marine, without silicate and with 1.5 mM  NH4Cl 
as nitrogen source; pH was adjusted to 7.4. Liquid cul-
tures were grown with agitation (150 rpm) in a volume of 
50–1000 ml. For transfection and long term storage cells 
were grown on solid f/2 plates supplemented with 1.3% 
agar and 75 µg/ml Zeocin. For antibody production cells 
were grown to an  OD600nm of 1.5 and antibody expression 
was induced by transferring cells to fresh f/2 medium 
containing 0.9  mM  NaNO3 but lacking ammonia. After 
2–3  days of antibody expression cells were removed by 
centrifugation (1500×g, 10  min) and the medium was 
filtered (⌀ 0.2  µm) [41]. Antibody within the medium 
was harvested by using centrifugal filter units (cut off of 
10 kDa), buffered in PBS and used directly for function-
ality assays without further purification steps. For ELISA 
the antibody was either used directly or purified with 
protein A agarose (ThermoScientific) according to manu-
facturer’s instructions. In case of the original hybridoma 
produced MARV NP antibody used for comparative 
analyses a Protein A-purified stock solution was utilized. 
The antibody concentration was measured as described 
previously [41] using the Easy Titer Mouse IgG Assay 
Kit, Easy Titer Rabbit IgG Assay Kit and the Easy Titer 
Human IgG (H + L) Assay Kit (ThermoScientific) accord-
ing to manufacture instructions with mouse, rabbit or 
human IgG as standard (500–15.6 ng/ml), respectively.
Western blot and ELISA
Antibody quality was initially analysed via SDS-PAGE and 
western blot analysis. Under reduced conditions standard 
SDS Laemmli buffer was used and samples were incu-
bated for 10 min at 96 °C. Under non reduced conditions 
no ß-mercaptoethanol but 20 mM NEM (N-ethylmalein-
imid) was added to the Laemmli buffer and samples were 
incubated for 10 min at 70 °C according to [52].
The ability of the antibody to bind to Marburg Virus 
NP protein was analysed by ELISA and western blot 
analysis. For ELISA analyses 150 ng of recombinant NP 
protein was coated to the wells over night as described 
previously [40]. After blocking and subsequent washing 
steps the wells were incubated with serial dilutions of 
algal produced antibody as well as the original antibody 
produced in hybridoma cells. Antibody bound to MARV 
NP was detected with an anti-mouse IgG secondary anti-
body coupled to HRP (Sigma-Aldrich). Medium of wild 
type cells, PBS and samples without NP protein served 
as negative controls. All measurements were carried out 
in triplicates. For western blot analysis, HuH7 cells were 
infected with Marburg virus as described below and cell 
extract was separated by SDS-PAGE. 500  ng/ml algal 
produced antibody and original antibody were used for 
NP binding. Depending on the primary antibody anti-
mouse, anti-rabbit and anti-human IgG secondary anti-
bodies coupled to HRP (Sigma-Aldrich) were used for 
detection.
Mammalian cell culture and MARV infection
HuH7 (human hepatoma) cells or Vero (african green 
monkey kidney) were cultivated with Dulbecco’s modi-
fied Eagle medium supplemented with penicillin and 
streptomycin, 5 mM glutamine and 10% fetal calf serum 
at 37 °C and 5%  CO2.
Infections with Marburg virus were performed under 
highest safety standards in the biosafety level 4 labora-
tory at the Institute of Virology, Philipps University Mar-
burg according to national safety regulations. Vero cells 
were infected with recombinant Marburg virus at a MOI 
of 0.1. Seven days post infection, cells were lysed by SDS 
treatment, boiled and lysates were used to perform SDS-
PAGE and western blot analyses.
Fluorescence microscopy
Phaeodactylum tricornutum cells were fixed with 4% 
PFA and 0.5% GA and localization of GFP fusion pro-
teins was analysed with a confocal laser scanning micro-
scope Leica TCS SP2 using a PL APO 63×/1.32–0.60, 
Oil Ph3 CS objective. GFP and chlorophyll were excited 
at 488 nm with an Ar 65 mW laser and fluorescence was 
detected at 500–520 and 680–720  nm, respectively. For 
immunofluorescence analyses, HuH7 cells on cover slips 
were infected with a MOI of 1. 20 h post infection, cells 
were fixed and virus was inactivated with 4% Paraform-
aldehyde for 16 h at 4 °C. Fresh 4% PFA was added to the 
cells before bringing them out of the BSL4 lab accord-
ing to our standard operating protocols. After the addi-
tional incubation with 4% PFA for 16  h at 4  °C, cells 
were treated with 100  mM Glycine in  PBSdef for block-
ing unspecific background binding and permeabilized 
with 0.1% Triton X100/PBSdef. Cover slips were stored in 
Blocking Buffer [2% BSA, 5% glycerine, 0.005% natrium 
azide, 0.2% Tween 20 in  PBSdef] until staining for no more 
than 5 days. Primary antibodies were used in a concen-
tration of 85 ng/µl.
Additional file
Additional file 1. Comparing functionality of purified algal and hybri‑
doma produced α MARV NP antibodies in ELISA. ELISA studies measuring 
the binding affinity for MARV NP protein revealed that the algal produced 
antibodies (protein A purified) bind to the protein, but affinity is reduced 
compared to the hybridoma produced antibodies. There was no signifi‑
cant difference in binding efficiency between antibodies taken directly 
from the algal medium (Fig. 2b) and purified algal antibodies. Error bars 
indicate standard deviation (n = 3).
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